No Data
No Data
Ocular Therapeutix, Inc. to Present at 43rd Annual J.P. Morgan Healthcare Conference in January 2025
Piper Sandler Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Raises Target Price to $21
Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK), Baxter International (BAX) and Ocular Therapeutix (OCUL)
H.C. Wainwright Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Maintains Target Price $15
Ocular Therapeutix Analyst Ratings
Promising Outlook for Ocular Therapeutix: Buy Rating Supported by Strong Market Demand and Financial Valuation
Unlock the Full List